$9.84 +0.16 (%) Immunogen Inc - NASDAQ

Nov. 21, 2014 | 04:00 PM

Partner Headlines

  1. Will ImmunoGen's Q4 Earnings Disappoint Again?

    GuruFocus | Jul. 30, 2014 | 19:21PM EST
  2. Wednesday's Biggest Movers

    Benzinga | Jun. 25, 2014 | 16:49PM EST
  3. Shares Of ImmunoGen Down On Morgan Stanley's Bearish Initiation

    Benzinga | Jun. 25, 2014 | 08:26AM EST
  4. Benzinga's Top Initiations

    Benzinga | Jun. 25, 2014 | 08:21AM EST
  5. UPDATE: Canaccord Genuity Initiates Coverage on ImmunoGen Ahead of Phase 3 Data

    Benzinga | Apr. 16, 2014 | 09:29AM EST
  6. ImmunoGen Says Initial Research Shows New Dosing Approach for IMGN853 Achieves Objective

    Benzinga | Apr. 8, 2014 | 16:17PM EST
  7. IDEXX Laboratories Elects Daniel Junius to Board of Directors

    Benzinga | Mar. 11, 2014 | 16:24PM EST
  8. US Stock Futures Down Ahead Of Wal-Mart Earnings, Economic Data

    Benzinga | Feb. 20, 2014 | 07:05AM EST
  9. CytomX Therapeutics, ImmunoGen Announce Strategic Collaboration

    Benzinga | Jan. 9, 2014 | 06:39AM EST
  10. ImmunoGen Announces Activity Reported with SAR3419 Plus Rituxan In Difficult-to-Treat Patient Population at ASH

    Benzinga | Dec. 9, 2013 | 11:31AM EST
  11. US Stock Futures Edge Lower Ahead Of FOMC Minutes, Economic Data

    Benzinga | Nov. 20, 2013 | 07:00AM EST
  12. ImmunoGen Announces Approval of Roche's Kadcyla in EU

    Benzinga | Nov. 20, 2013 | 05:56AM EST
  13. UPDATE: Morgan Stanley Downgrades ImmunoGen Following Phase 2 Failure of IMGN901

    Benzinga | Nov. 11, 2013 | 10:00AM EST
  14. Benzinga's Top #PreMarket Losers

    Benzinga | Nov. 11, 2013 | 08:19AM EST
  15. ImmunoGen Announces License Agreement with Novartis

    Benzinga | Nov. 11, 2013 | 06:38AM EST
  16. Mid-Afternoon Market Update: Marvell Rises on KKR Stake While Orbitz Gives Up Last Week's Gains

    Benzinga | Nov. 5, 2013 | 15:23PM EST
  17. Mid-Day Market Update: BroadSoft Drops On Q3 Results; Endo Health Shares Spike Higher

    Benzinga | Nov. 5, 2013 | 12:29PM EST
  18. Mid-Morning Market Update: Markets Open Lower; CVS Caremark Lifts Outlook

    Benzinga | Nov. 5, 2013 | 10:36AM EST
  19. Benzinga's Top #PreMarket Losers

    Benzinga | Nov. 5, 2013 | 08:16AM EST
  20. US Stock Futures Signal Lower Start On Wall Street

    Benzinga | Nov. 5, 2013 | 07:11AM EST
  21. ImmunoGen Presents SAR566658 Clinical Findings at AACR-NCI-EORTC Conference

    Benzinga | Oct. 20, 2013 | 17:00PM EST
  22. US Stock Futures Up; J.P. Morgan Earnings In Focus

    Benzinga | Oct. 11, 2013 | 07:13AM EST
  23. ImmunoGen Announces New License Agreement with Novartis

    Benzinga | Oct. 11, 2013 | 06:54AM EST
  24. ImmunoGen Announces Positive Results from Kadcyla Phase III Trial, TH3RESA at ECC 2013

    Benzinga | Sep. 28, 2013 | 09:23AM EST
  25. The 'L' In CANSLIM Stands For Leaders, Not Laggards

    IBD | Sep. 11, 2013 | 18:29PM EST
  26. UPDATE: Oppenheimer Downgrades ImmunoGen to Perform on Valuation

    Benzinga | Jan. 28, 2013 | 02:30AM EST
  27. Earnings Scheduled For January 25, 2013

    Benzinga | Jan. 24, 2013 | 19:53PM EST
  28. From Earlier: Amgen Takes Third License for Rights to Use ImmunoGen's TAP Technology

    Benzinga | Dec. 19, 2012 | 02:10AM EST
  29. ImmunoGen Clinical Results of IMGN901

    Benzinga | Dec. 10, 2012 | 09:52AM EST
  30. A Peek Into the Market Before the Trading Begins

    Benzinga | Nov. 26, 2012 | 01:40AM EST
  31. ImmunoGen Announces Dr. Charles Morris as New Chief Development Officer

    Benzinga | Nov. 25, 2012 | 23:33PM EST
  32. ImmunoGen Inc. Reports Operating Results (10-Q)

    GuruFocus | Oct. 31, 2012 | 07:02AM EST
  33. It's All Bad News For ImmunoGen After 1Q13 Earnings Release

    Benzinga | Oct. 26, 2012 | 10:07AM EST
  34. Health Care Sector Wrap

    FoxBusiness | Aug. 27, 2012 | 10:44AM EST
  35. Benzinga's Top Pre-Market Gainers

    Benzinga | Aug. 27, 2012 | 02:13AM EST
  36. A Peek Into The Market Before The Trading Starts

    Benzinga | Aug. 27, 2012 | 01:22AM EST
  37. ImmunoGen

    IBD | Aug. 22, 2012 | 12:46PM EST
  38. Health Care Sector Wrap

    FoxBusiness | Aug. 15, 2012 | 10:43AM EST
  39. UPDATE: J.P. Morgan Reiterates Neutral Rating, Raises PT on ImmunoGen

    Benzinga | Aug. 6, 2012 | 05:17AM EST
  40. Infosys Ltd ADR, Kroger Among Stocks Down on High Volume Thursday

    FoxBusiness | Jul. 12, 2012 | 06:48AM EST
  41. Benzinga's Top Pre-Market Losers

    Benzinga | Jul. 12, 2012 | 02:24AM EST
  42. ImmunoGen, Inc. Initiates Phase I Trial of IMGN853 in Ovarian Cancer and Other Solid Tumors Over-Expressing Its Folate Receptor Target

    Benzinga | Jul. 11, 2012 | 00:33AM EST
  43. Benzinga's Initiation Summary for June 14, 2012

    Benzinga | Jun. 14, 2012 | 06:21AM EST
  44. UPDATE: Cantor Fitzgerald Initiates Hold, $15 PT on ImmmunoGen; In Need of Additional Catalyst

    Benzinga | Jun. 14, 2012 | 04:02AM EST
  45. From Earlier: ImmunoGen Announces Development of Trastuzumab Emtansine for Early Stage HER2-Positive Breast Cancer

    Benzinga | Jun. 4, 2012 | 02:20AM EST
  46. From Earlier: ImmunoGen Announces Results from Trastuzumab Emtansine (T-DM1) EMILIA Phase III Trial

    Benzinga | Jun. 4, 2012 | 02:15AM EST
  47. Stocks Set to Close Quarter on High Note with Finish Line (FINL) and Research in Motion (RIMM) on the Move

    MarketIntelligenceCenter | Mar. 30, 2012 | 10:48AM EST
  48. ImmunoGen Inc. Reports Operating Results (10-Q)

    GuruFocus | Jan. 31, 2012 | 04:06AM EST
  49. ImmunoGen Up 7% After Earnings Beat

    Benzinga | Jan. 31, 2012 | 02:19AM EST
  50. ImmunoGen

    IBD | Jan. 27, 2012 | 11:24AM EST
Trading Center